Question 18182 — pharmacy and medicines

Summary

Mr. Bruno Fuchs questions the Minister of Solidarity and Health on the problem of the cost of generic medicines in France. Since 1996, successive governments have encouraged the development of generic drugs with the aim of offering the same quality and therapeutic effectiveness as an original drug, the patent for which has fallen into the public domain. The major advantage of these generic drugs is their cost less for the consumer and therefore for the primary health insurance fund. This is why since 1999, pharmacists have been authorized to replace original medicines with their generic equivalents. In 2018, only 36% of medicines reimbursed by the primary health insurance fund are generics compared to 80% of medicines in Germany. The numbers are even more worrying when comparing their prices. Of the Studies have shown that the price of generic drugs is significantly higher for the French than for their European neighbors while France wants to be at the forefront on the social aspect. Advertisements produced today by generic laboratories are proof that the margins achieved are comfortable, even very comfortable. Generic drugs were also intended to allow the primary fund health insurance to make savings, this to ensure the French have the best care at the best price and that it is and remains accessible to all. He questions him about the strategies planned by the Government to finally achieve reasonable and fairer prices for generic medicines in France.

Machine translation from French. The official text remains authoritative.

Timeline

No timeline events have been ingested for this record yet.

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

No documents linked.

Sponsors

No sponsors or actors listed by the source.

Related records

No cross-record relationships stored yet.